Literature DB >> 20234191

PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments.

Isabelle Tanjoni1, Colin Walsh, Sean Uryu, Alok Tomar, Ju-Ock Nam, Ainhoa Mielgo, Ssang-Taek Lim, Congxin Liang, Marcel Koenig, Connie Sun, Neela Patel, Cheni Kwok, Gerald McMahon, Dwayne G Stupack, David D Schlaepfer.   

Abstract

Tumor cells can grow in an anchorage-independent manner. This is mediated in part through survival signals that bypass normal growth restraints controlled by integrin cell surface receptors. Focal adhesion kinase (FAK) is a cytoplasmic protein-tyrosine kinase that associates with integrins and modulates various cellular processes including growth, survival, and migration. As increased FAK expression and tyrosine phosphorylation are associated with tumor progression, inhibitors of FAK are being tested for anti-tumor effects. Here, we analyze PND-1186, a substituted pyridine reversible inhibitor of FAK activity with a 50% inhibitory concentration (IC50) of 1.5 nM in vitro. PND-1186 has an IC50 of ~100 nM in breast carcinoma cells as determined by anti-phospho-specific immunoblotting to FAK Tyr-397. PND-1186 did not alter c‑Src or p130Cas tyrosine phosphorylation in adherent cells, yet functioned to restrain cell movement. Notably, 1.0 µM PND-1186 (>5-fold above IC50) had limited effects on cell proliferation. However, under non-adherent conditions as spheroids and as colonies in soft agar, 0.1 µM PND-1186 blocked FAK and p130Cas tyrosine phosphorylation, promoted caspase-3 activation, and triggered cell apoptosis. PND-1186 inhibited 4T1 breast carcinoma subcutaneous tumor growth correlated with elevated tumor cell apoptosis and caspase 3 activation. Addition of PND-1186 to the drinking water of mice was well tolerated and inhibited ascites- and peritoneal membrane-associated ovarian carcinoma tumor growth associated with the inhibition of FAK Tyr-397 phosphorylation. Our results with low-level PND-1186 treatment support the conclusion that FAK activity selectively promotes tumor cell survival in three-dimensional environments.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20234191      PMCID: PMC2933317          DOI: 10.4161/cbt.9.10.11434

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  42 in total

1.  Force sensing by mechanical extension of the Src family kinase substrate p130Cas.

Authors:  Yasuhiro Sawada; Masako Tamada; Benjamin J Dubin-Thaler; Oksana Cherniavskaya; Ryuichi Sakai; Sakae Tanaka; Michael P Sheetz
Journal:  Cell       Date:  2006-12-01       Impact factor: 41.582

Review 2.  p130Cas: a versatile scaffold in signaling networks.

Authors:  Paola Defilippi; Paola Di Stefano; Sara Cabodi
Journal:  Trends Cell Biol       Date:  2006-04-03       Impact factor: 20.808

Review 3.  Integrin-regulated FAK-Src signaling in normal and cancer cells.

Authors:  Satyajit K Mitra; David D Schlaepfer
Journal:  Curr Opin Cell Biol       Date:  2006-08-17       Impact factor: 8.382

4.  A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.

Authors:  Qing Shi; Anita B Hjelmeland; Stephen T Keir; Linhua Song; Sarah Wickman; Dowdy Jackson; Osamu Ohmori; Darell D Bigner; Henry S Friedman; Jeremy N Rich
Journal:  Mol Carcinog       Date:  2007-06       Impact factor: 4.784

5.  Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation.

Authors:  Maroesja J van Nimwegen; Saertje Verkoeijen; Liesbeth van Buren; Danny Burg; Bob van de Water
Journal:  Cancer Res       Date:  2005-06-01       Impact factor: 12.701

6.  Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.

Authors:  Ta-Jen Liu; Tiffany LaFortune; Toshiyuki Honda; Osamu Ohmori; Shinji Hatakeyama; Thomas Meyer; Dowdy Jackson; John de Groot; W K Alfred Yung
Journal:  Mol Cancer Ther       Date:  2007-04       Impact factor: 6.261

7.  p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.

Authors:  Sara Cabodi; Agata Tinnirello; Paola Di Stefano; Brigitte Bisarò; Elena Ambrosino; Isabella Castellano; Anna Sapino; Riccardo Arisio; Federica Cavallo; Guido Forni; Marina Glukhova; Lorenzo Silengo; Fiorella Altruda; Emilia Turco; Guido Tarone; Paola Defilippi
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

Review 8.  The role of focal-adhesion kinase in cancer - a new therapeutic opportunity.

Authors:  Gordon W McLean; Neil O Carragher; Egle Avizienyte; Jeff Evans; Valerie G Brunton; Margaret C Frame
Journal:  Nat Rev Cancer       Date:  2005-07       Impact factor: 60.716

9.  Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model.

Authors:  S K Mitra; S-T Lim; A Chi; D D Schlaepfer
Journal:  Oncogene       Date:  2006-03-20       Impact factor: 9.867

10.  Cellular characterization of a novel focal adhesion kinase inhibitor.

Authors:  Jill K Slack-Davis; Karen H Martin; Robert W Tilghman; Marcin Iwanicki; Ethan J Ung; Christopher Autry; Michael J Luzzio; Beth Cooper; John C Kath; W Gregory Roberts; J Thomas Parsons
Journal:  J Biol Chem       Date:  2007-03-28       Impact factor: 5.157

View more
  80 in total

1.  A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo.

Authors:  Vita M Golubovskaya; Sheila Figel; Baotran T Ho; Christopher P Johnson; Michael Yemma; Grace Huang; Min Zheng; Carl Nyberg; Andrew Magis; David A Ostrov; Irwin H Gelman; William G Cance
Journal:  Carcinogenesis       Date:  2012-03-07       Impact factor: 4.944

2.  Enterolobium contortisiliquum trypsin inhibitor (EcTI), a plant proteinase inhibitor, decreases in vitro cell adhesion and invasion by inhibition of Src protein-focal adhesion kinase (FAK) signaling pathways.

Authors:  Cláudia Alessandra Andrade de Paula; Vivien Jane Coulson-Thomas; Joana Gasperazzo Ferreira; Paloma Korehisa Maza; Erika Suzuki; Adriana Miti Nakahata; Helena Bonciani Nader; Misako Uemura Sampaio; Maria Luiza V Oliva
Journal:  J Biol Chem       Date:  2011-10-28       Impact factor: 5.157

3.  Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.

Authors:  Colin Walsh; Isabelle Tanjoni; Sean Uryu; Alok Tomar; Ju-Ock Nam; Hong Luo; Angelica Phillips; Neela Patel; Cheni Kwok; Gerald McMahon; Dwayne G Stupack; David D Schlaepfer
Journal:  Cancer Biol Ther       Date:  2010-05-15       Impact factor: 4.742

Review 4.  Targeting the p53 pathway.

Authors:  Vita M Golubovskaya; William G Cance
Journal:  Surg Oncol Clin N Am       Date:  2013-07-30       Impact factor: 3.495

5.  Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors.

Authors:  Timothy A Marlowe; Felicia L Lenzo; Sheila A Figel; Abigail T Grapes; William G Cance
Journal:  Mol Cancer Ther       Date:  2016-09-16       Impact factor: 6.261

6.  Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression.

Authors:  Kristy K Ward; Isabelle Tancioni; Christine Lawson; Nichol L G Miller; Christine Jean; Xiao Lei Chen; Sean Uryu; Josephine Kim; David Tarin; Dwayne G Stupack; Steven C Plaxe; David D Schlaepfer
Journal:  Clin Exp Metastasis       Date:  2012-12-30       Impact factor: 5.150

7.  Knock-in mutation reveals an essential role for focal adhesion kinase activity in blood vessel morphogenesis and cell motility-polarity but not cell proliferation.

Authors:  Ssang-Taek Lim; Xiao Lei Chen; Alok Tomar; Nichol L G Miller; Jiyeon Yoo; David D Schlaepfer
Journal:  J Biol Chem       Date:  2010-05-04       Impact factor: 5.157

Review 8.  FAK in cancer: mechanistic findings and clinical applications.

Authors:  Florian J Sulzmaier; Christine Jean; David D Schlaepfer
Journal:  Nat Rev Cancer       Date:  2014-08-07       Impact factor: 60.716

9.  Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.

Authors:  Vita M Golubovskaya; Grace Huang; Baotran Ho; Michael Yemma; Carl D Morrison; Jisook Lee; Brian P Eliceiri; William G Cance
Journal:  Mol Cancer Ther       Date:  2012-12-12       Impact factor: 6.261

Review 10.  RhoGEFs in cell motility: novel links between Rgnef and focal adhesion kinase.

Authors:  N L G Miller; E G Kleinschmidt; D D Schlaepfer
Journal:  Curr Mol Med       Date:  2014-02       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.